ONCIN — Oncoinvent ASA Share News
0.000.00%
Last trade - 00:00- NOK305.43m
- NOK200.69m
- NOK28.07m
Brief: Bergenbio Announces Amendment To Accord Clinical Trial Protocol For Bemcentinib As Potential Treatment For Covid-19
Brief: BerGenBio: Final Results Of Subsequent Offering
Brief: BerGenBio Gets Subscriptions For 534,178 Offer Shares In Subsequent Offering
Brief: Bergenbio Announces Positive Interim Clinical And Translational Data From Phase II Trial Of Bemcentinib In Combination With Keytruda
Brief: BerGenBio To Carry Out Share Capital Increase In Connection With Subsequent Offering
Brief: Bergenbio: First Covid19 Patient Dosed With Bemcentinib In Accord Trial
Brief: Bergenbio Q1 Operating Loss Widens To NOK 56.2 Mln
Brief: Bergenbio Raises NOK 500 Mln Through Private Placement
Brief: BerGenBio Contemplates Private Placement
BerGenBio shares soar on COVID-19 drug trial news (updated)
BerGenBio shares more than double on COVID-19 drug trial news
Brief: Bergenbio's Bemcentinib Selected To Be Fast-Tracked
Brief: Bergenbio's Bemcentinib Selected To Be Fast-Tracked As Potential Treatment For COVID-19
Brief: Bergenbio Provides COVID-19 Impact Assessment
Brief: Bergenbio Q4 Operating Loss Widens To NOK 59.1 Million
Brief: Bergenbio ASA Announces Potential Subsequent Offering Of Up To 1.5 Mln New Shares
Brief: Bergenbio ASA Says Private Placement Successfully Placed
Brief: Bergenbio: Contemplated Private Placement
Brief: BerGenBio Meets Efficacy Endpoint For First Stage Of Phase II Trial With AXL Inhibitor Bemcentinib In Combination With Keytruda In NSCLC Patients Progressing On Immune Checkpoint Inhibitors